National Advisory Committee on Immunization

Related links

About NACI

The National Advisory Committee on Immunization (NACI) is a national advisory committee of experts in the fields of pediatrics, infectious diseases, immunology, medical microbiology, internal medicine and public health. The Committee reports to the Assistant Deputy Minister of Infectious Disease Prevention and Control, and works with staff of the Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada to provide ongoing and timely medical, scientific and public health advice.

NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are included in published literature reviews, statements and updates. NACI recommendations are also published in the Canadian Immunization Guide. Email updates are available through our mailing list.

Subscribe for updates

NACI recommendations, statements and updates

Subject* Title Date
Pertussis, Tetanus and Diphtheria Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine 2018
Pertussis, Tetanus and Diphtheria Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness 2018
Bacille Calmette Guérin (BCG) Statement on Bacille Calmette Guérin (BCG) Vaccine - Erratum (2005) 2004
Cholear Implant Recipients Immunization Recommendations for Cochlear Implant Recipients 2003
Haemophilus Influenzae Type B Statement on the recommended use of pentavalent and hexavalent vaccines 2007
Haemophilus Influenzae Type B Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, haemophilus Influenzae Type B  Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age 2005
Hepatitis Update on the recommended use of Hepatitis B vaccine 2017
Hepatitis Update on the Recommended use of Hepatitis A Vaccine 2016
Hepatitis Statement on the recommended use of pentavalent and hexavalent vaccines 2007
Hepatitis Update on hepatitis A vaccine (AVAXIM®, Aventis Pasteur) 2001
Hepatitis Statement on Alternate Adolescent Schedule for Hepatitis B Vaccine 2000
Hepatitis Supplementary Statement on Hepatitis A Vaccine 2000
Hepatitis Supplementary statement on hepatitis prevention - hepatitis A and hepatitis B combination vaccine for children 1999
Hepatitis Statement on combination vaccines against hepatitis A and hepatitis B 1999
Human Papillomavirus Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations 2017
Human Papillomavirus NACI Literature Review for HPV Immunization of Immunocompromised Populations 2017
Human Papillomavirus Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule 2016
Human Papillomavirus

Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule

Amendment to the 2015 "Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule"

 2015
Human Papillomavirus Update on Human Papillomavirus (HPV) Vaccines 2012
Human Papillomavirus Statement on Human Papillomavirus Vaccine 2007
Human Papillomavirus Literature review on HPV 6, 11, 16 and 18: Disease and Vaccine Characteristics 2007
Immunization Evidence-based recommendations for immunization - Methods of the National Advisory Committee on Immunization 2009
Influenza Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017–2018 2017
Influenza National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017 2016
Influenza Literature Review of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older 2016
Influenza Literature Review on Pediatric Fluad® Influenza Vaccine Use in Children 6-72 Months of Age 2015
Influenza National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2015-2016 2015
Influenza Opinion on Live Attenuated Influenza Vaccine (LAIV) Effectiveness in Young Children 2015
Influenza Influenza Vaccine Effectiveness, Immunogenicity, and Safety in Healthy Adults 19-64 Years Old 2014
Influenza Literature Review on Influenza Vaccination in Healthy 5-18-Year-Olds 2014
Influenza Literature Review on Quadrivalent Influenza Vaccines 2014
Influenza Statement on Seasonal Influenza Vaccine for 2014-2015 2014
Influenza Statement on Seasonal Influenza Vaccine for 2013-2014
Revised Wording to the National Advisory Committee on Immunization (NACI) Recommendation for Live Attenuated Influenza Vaccine (LAIV) in Healthy Children and Adolescents 2-17 Years of Age 		2013
Influenza Statement on Seasonal Influenza Vaccine for 2012-2013 2012
Influenza Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 2011
Influenza Recommendations on the use of MF59-Adjuvanted Trivalent Influenza Vaccine (Fluad®): Supplemental Statement of Seasonal Influenza Vaccine for 2011-2012 2011
Influenza Statement on Seasonal Influenza Vaccine for 2011-2012 2011
Influenza Addendum to the 2010-2011 Seasonal Trivalent Inactivated Influenza Vaccine 2011
Influenza Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011 2010
Influenza Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2009-2010 2009
Influenza Statement on Influenza Vaccination for the 2008-2009 Season 2008
Influenza Statement on Influenza Vaccination for the 2007-2008 Season 2007
Influenza Statement on Influenza Vaccination for the 2006-2007 Season 2006
Influenza Update on Influenza Vaccination for the 2005-2006 Season 2006
Influenza Statement on Influenza Vaccination for the 2005-2006 Season 2005
Influenza Statement on Influenza Vaccination for the 2004-2005 Season 2004
Influenza Statement on Influenza Vaccination for the 2003-2004 Season 2003
Influenza Supplementary Statement for the 2002-2003 Influenza Season: Update on Oculo-respiratory Syndrome in Association with Influenza Vaccination 2002
Influenza Statement on Influenza Vaccination for the 2002-2003 Season 2002
Influenza Supplementary Statement for the 2001-2002 Season: Influenza Vaccination of Persons Who Experienced Oculo-Respiratory Syndrome Following Previous Influenza Vaccination (ACS-7) 2001
Influenza Statement on Influenza Vaccination for the 2001-2002 Season (ACS-4) 2001
Influenza Supplementary statement on influenza vaccination: continued use of Fluviral® influenza vaccine in the 2000-2001 season (ACS-1) 2001
Influenza Statement on Influenza Vaccination for the 2000-2001 Season 2000
Measles Statement on Measles-Mumps-Rubella-Varicella Vaccine 2010
Measles Measles Surveillance: Guidelines for Laboratory Support 1998
Measles Interim Advisory on Measles Revaccination of Persons with Acquired Immunodeficiency Syndrome (AIDS) 1996
Measles Supplementary Statement on Measles Elimination in Canada 1996
Measles Guidelines for Control of Measles Outbreaks in Canada 1995
Meningococcal Disease Update on Quadrivalent Meningococcal Vaccines available in Canada 2015
Meningococcal Disease Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine 2014
Meningococcal Disease Literature review on serogroup B invasive meningococcal disease: epidemiology, multicomponent meningococcal B vaccine characteristics and other factors for consideration 2014
Meningococcal Disease Advice for the use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine 2014
Meningococcal Disease

Update on the Use of Quadrivalent Conjugate Meningococcal Vaccines

 2013
Meningococcal Disease

Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations

 2009
Meningococcal Disease Meningococcal C Conjugate for Infants statement 2007
Meningococcal Disease Statement on Conjugate Meningococcal Vaccine for Serogroups A,C, Y and W135 2007
Meningococcal Disease Update on Meningococcal C Conjugate Vaccines 2005
Meningococcal Disease Supplementary Statement on Conjugate Meningococcal Vaccines 2003
Meningococcal Disease Statement on Recommended Use of Meningococcal Vaccines
 
 2001
MMR (Measles, Mumps, Rubella) Supplementary Statement on MMR Vaccine and Anaphylactic Hypersensitivity to Egg or Egg-Related Antigens 1996
MMRV (Measles, Mumps, Rubella, Varicella) Statement on Measles-Mumps-Rubella-Varicella Vaccine 2010
MMRV (Measles, Mumps, Rubella, Varicella, Febrile Seizures) Update on Measles-Mumps-Rubella-Varicella Vaccine and Febrile Seizures 2016
Mumps Statement on Measles-Mumps-Rubella-Varicella Vaccine 2010
Mumps Guidelines for the Prevention and Control of Mumps Outbreaks in Canada 2010
Mumps Statement on Mumps Vaccine 2007
Pertussis, Tetanus, and Diphtheria Update on Pertussis Vaccination in Pregnancy 2014
Pertussis, Tetanus, and Diphtheria Statement on the Booster for 4-6 year-olds for Protection against Pertussis 2014
Pertussis, Tetanus, and Diphtheria Statement on the recommended use of pentavalent and hexavalent vaccines 2007
Pertussis, Tetanus, and Diphtheria Literature review on DTaP based penta- and hexavalent vaccines approved for clinical use in Canada 2006
Pertussis, Tetanus, and Diphtheria Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis 2005
Pertussis, Tetanus, and Diphtheria Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, Haemophilus Influenzae Type B Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age 2005
Pertussis, Tetanus, and Diphtheria Clarification - Prevention of Pertussis in Adolescents and Adults 2004
Pertussis, Tetanus, and Diphtheria Prevention of Pertussis in Adolescents and Adults 2003
Pertussis, Tetanus, and Diphtheria Statement on Adult/Adolescent Formulation of Combined Acellular Pertussis, Tetanus, and Diphtheria Vaccine 2000
Pneumococcus Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older – Interim Recommendation 2016
Pneumococcus Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23) 2015
Pneumococcus Update on the Use of Pneumococcal Vaccines: Addition of Asthma as a High-Risk Condition 2014
Pneumococcus Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13) 2013
Pneumococcus Update on the Use of Conjugate Pneumococcal Vaccines in Childhood 2010
Pneumococcus Update on Pediatric Invasive Pneumococcal Disease and Recommended Use of Conjugate Pneumococcal Vaccines 2010
Pneumococcus Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users 2008
Pneumococcus Update On the Recommendations For The Routine Use of Pneumococcal Conjugate Vaccine For Infants 2006
Pneumococcus Recommendations for use of Pneumococcal 23-Valent Polysaccharide Vaccine During Shortage 2004
Pneumococcus Statement on the Recommended Use of Pneumococcal Conjugate Vaccine: Addendum 2003
Pneumococcus Statement On Recommended Use Of Pneumococcal Conjugate Vaccine 2002
Poliomyelitis Statement on the recommended use of pentavalent and hexavalent vaccines 2007
Poliomyelitis Interchangeability of Diphtheria, Tetanus, Acellular Pertussis, Polio, haemophilus Influenzae Type B  Combination Vaccines Presently Approved for Use in Canada for Children < 7 Years of Age 2005
Rabies Vaccines Recommendations Regarding the Management of Bat Exposures to Prevent Human Rabies 2009
Rabies Vaccines Update on Rabies Vaccines 2005
Respiratory Syncytial Virus (RSV) Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab) 2003
Rotavirus Statement on Rotavirus Vaccines and Intussusception 2016
Rotavirus Literature Review on Rotavirus: Disease and Vaccine Characteristics 2010
Rotavirus Updated Statement on the use of Rotavirus Vaccines 2010
Rotavirus Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine 2008
Rubella Statement on Measles-Mumps-Rubella-Varicella Vaccine 2010
Smallpox Statement on Smallpox Vaccination 2002
Thimerosal in Vaccines Thimerosal: Updated Statement 2007
Thimerosal in Vaccines Updated Recommendations on the use of Thimerosal-Containing Vaccines in Canada 2005
Thimerosal in Vaccines Statement on Thimerosal 2003
Thimerosal in Vaccines Thimerosal in Vaccines 1999
Varicella Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients 2016
Varicella Varicella Proof of Immunity - 2015 Update 2015
Varicella Update on the Use of Herpes Zoster Vaccine 2014
Varicella Literature Review on One-Dose and Two-Dose Varicella Vaccination 2010
Varicella Statement on Measles-Mumps-Rubella-Varicella Vaccine 2010
Varicella Varicella Vaccination Two-Dose Recommendations. 2010
Varicella Updated Recommendations For The Use Of Varicella And MMR Vaccines In HIV-infected Individuals 2010
Varicella Statement on the Recommended Use of Herpes Zoster Vaccine 2010
Varicella Varizig™ as the varicella zoster immune globulin for the prevention of varicella In at-risk patients 2006
Varicella Update on Varicella 2004
Varicella NACI Update to Statement on Varicella Vaccine 2002
Varicella Statement on Recommended Use of Varicella Virus Vaccine 1999
Report a problem or mistake on this page

Privacy statement

The information you provide through this survey is collected under the authority of the Department of Employment and Social Development Act (DESDA) for the purpose of measuring the performance of Canada.ca and continually improving the website. Your participation is voluntary.

Please do not include sensitive personal information in the message box, such as your name, address, Social Insurance Number, personal finances, medical or work history or any other information by which you or anyone else can be identified by your comments or views.

Any personal information collected will be administered in accordance with the Department of Employment and Social Development Act, the Privacy Act and other applicable privacy laws governing the protection of personal information under the control of the Department of Employment and Social Development. Survey responses will not be attributed to individuals.

If you wish to obtain information related to this survey, you may submit a request to the Department of Employment and Social Development pursuant to the Access to Information Act. Instructions for making a request are provided in the publication InfoSource, copies of which are located in local Service Canada Centres.

You have the right to file a complaint with the Privacy Commissioner of Canada regarding the institution’s handling of your personal information at: How to file a complaint.

When making a request, please refer to the name of this survey: Report a Problem or Mistake on This Page.

Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: